BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 25941226)

  • 1. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
    Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
    Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
    Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system.
    Schena E; Nedialkova L; Borroni E; Battaglia S; Cabibbe AM; Niemann S; Utpatel C; Merker M; Trovato A; Hofmann-Thiel S; Hoffmann H; Cirillo DM
    J Antimicrob Chemother; 2016 Jun; 71(6):1532-9. PubMed ID: 27076101
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
    Torrea G; Coeck N; Desmaretz C; Van De Parre T; Van Poucke T; Lounis N; de Jong BC; Rigouts L
    J Antimicrob Chemother; 2015 Aug; 70(8):2300-5. PubMed ID: 25977401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region.
    Lopez B; Siqueira de Oliveira R; Pinhata JMW; Chimara E; Pacheco Ascencio E; Puyén Guerra ZM; Wainmayer I; Simboli N; Del Granado M; Palomino JC; Ritacco V; Martin A
    J Antimicrob Chemother; 2019 Feb; 74(2):373-379. PubMed ID: 30358851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Those who cannot remember the past are condemned to repeat it': Drug-susceptibility testing for bedaquiline and delamanid.
    Köser CU; Maurer FP; Kranzer K
    Int J Infect Dis; 2019 Mar; 80S():S32-S35. PubMed ID: 30818049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
    Hoffmann H; Kohl TA; Hofmann-Thiel S; Merker M; Beckert P; Jaton K; Nedialkova L; Sahalchyk E; Rothe T; Keller PM; Niemann S
    Am J Respir Crit Care Med; 2016 Feb; 193(3):337-40. PubMed ID: 26829425
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
    Juréen P; Angeby K; Sturegård E; Chryssanthou E; Giske CG; Werngren J; Nordvall M; Johansson A; Kahlmeter G; Hoffner S; Schön T
    J Clin Microbiol; 2010 May; 48(5):1853-8. PubMed ID: 20237102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.